Cyclo Therapeutics Net Income 2006-2021 | CYTH

Cyclo Therapeutics net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Cyclo Therapeutics Annual Net Income
(Millions of US $)
2020 $-9
2019 $-8
2018 $-4
2017 $-4
2016 $-4
2015 $-3
2014 $-1
2013 $0
2012 $0
2011 $-0
2010 $-0
2009 $-0
2008 $-0
2007 $1
2006 $-0
2005 $-0
Cyclo Therapeutics Quarterly Net Income
(Millions of US $)
2021-06-30 $-4
2021-03-31 $-4
2020-12-31 $-3
2020-09-30 $-1
2020-06-30 $-2
2020-03-31 $-3
2019-12-31 $-3
2019-09-30 $-2
2019-06-30 $-1
2019-03-31 $-2
2018-12-31 $-1
2018-09-30 $-1
2018-06-30 $-1
2018-03-31 $-1
2017-12-31 $-1
2017-09-30 $-1
2017-06-30 $-1
2017-03-31 $-1
2016-12-31 $-1
2016-09-30 $-2
2016-06-30 $-1
2016-03-31 $-1
2015-12-31 $-1
2015-09-30 $-1
2015-06-30 $-0
2015-03-31 $-0
2014-12-31 $-0
2014-09-30 $-0
2014-06-30 $-0
2014-03-31 $0
2013-12-31
2013-09-30
2013-06-30 $0
2013-03-31 $0
2012-12-31
2012-09-30
2012-06-30 $-0
2012-03-31 $0
2011-12-31 $-0
2011-09-30 $0
2011-06-30 $0
2011-03-31 $-0
2010-12-31 $0
2010-09-30 $-0
2010-06-30 $0
2010-03-31 $-0
2009-12-31 $-0
2009-09-30 $0
2009-06-30 $-0
2009-03-31 $-0
2008-12-31 $-0
2008-09-30 $0
2008-06-30 $-0
2008-03-31 $-0
2007-12-31 $0
2007-09-30 $0
2007-06-30 $0
2007-03-31 $0
2006-12-31 $-0
2006-09-30 $-0
2006-06-30 $-0
2006-03-31 $-0
2005-12-31 $-0
2005-09-30 $-0
2005-06-30 $0
2005-03-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.044B $0.001B
Cyclo Therapeutics Inc. is a clinical-stage biotechnology company. It develops cyclodextrin-based products for the treatment of disease. The company's Trappsol(R) Cyclo(TM), an orphan drug designated product primarily in the United States and Europe, is in ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease. Cyclo Therapeutics Inc., formerly known as CTD Holdings Inc., is based in ALACHUA, Fla.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.038B 8.59
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.127B 20.54
Biohaven Pharmaceutical Holding (BHVN) United States $8.605B 0.00
Emergent Biosolutions (EBS) United States $2.673B 6.45
Arcus Biosciences (RCUS) United States $2.441B 0.00
Myovant Sciences (MYOV) United Kingdom $1.860B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.754B 0.00
Zymeworks (ZYME) Canada $1.075B 0.00
Ambrx Biopharma (AMAM) United States $0.524B 0.00
SQZ Biotechnologies (SQZ) United States $0.335B 0.00
Enzo Biochem (ENZ) United States $0.158B 15.48